Unsplash+Artificial IntelligenceNovo Nordisk is going all in on AINovo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is … more ➔
Sofinnova PartnersCapitalCan Europe finance and keep its biotech winners?The recent resurgence of life sciences IPOs in the US highlights a persistent structural imbalance: Europe generates world-class science but struggles to finance and retain it. The European Life … more ➔
www.istockphoto.com/YuriVenture StudiosEurope’s distinct biotech venture studio modelFor decades, biotech companies were formed around a discovery: a promising biological signal, a novel target, a platform emerging from academic research. Now a different formation model is gaining momentum: … more ➔
Adcendo ApSFinancingAdcendo banks US$75m to push ADC pipeline forwardCopenhagen-based biotech Adcendo ApS has closed an oversubscribed US$75 million Series C round led by Jeito Capital. The funds will fuel early-phase trials of three ADC candidates for cancers with high … more ➔
Pic by Susan Wilkinson via UnsplashFinancingClean Food Group to scale yeast-based oils with £4.5m in the bankClean Food Group has secured £4.5 million from a group of investors led by Clean Growth Fund and New Agrarian, together with £700,000 in non-dilutive funding from Innovate UK. The London-based biotech … more ➔
BioNTechClinical TrialsBioNTech reports promising Phase II data for uterine cancer ADCMainz‑based biotech BioNTech has presented compelling Phase II data for its compound trastuzumab pamirtecan. The antibody–drug conjugate (ADC) was evaluated in patients with advanced uterine cancer … more ➔
David Dorward; Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)AMRBasilea lands US$6m CARB X boost for novel antibioticAmid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative … more ➔
Pic by Immo Wegmann via UnsplashFundingJeito Capital raises record US$1.2bn to bankroll European biopharma’s next generationJeito Capital has closed its second dedicated biopharma fund, Jeito II, on a record US$1.2 billion (€1 billion), making it the largest fund ever raised by a fully independent European biopharma-focused … more ➔
Tubulis GmbHAcquisitionGilead acquires German ADC specialist Tubulis in US$5bn dealFor Tubulis, the time for an exit has arrived: US based pharma group Gilead is set to pay up to US$5bn for the biotech’s ADC expertise. more ➔
VanessaSpencer - stock.adobe.comBiotech ClusterPortugal’s biotech industry is growing upFor years, Portugal sat just outside Europe’s main biotech conversation: scientifically credible, strong in research, but too small, too fragmented and too thinly financed to compete with the established … more ➔
Unsplash+
Sofinnova Partners
www.istockphoto.com/Yuri
Adcendo ApS
Pic by Susan Wilkinson via Unsplash
BioNTech
David Dorward; Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)
Pic by Immo Wegmann via Unsplash
Tubulis GmbH
VanessaSpencer - stock.adobe.com